| ULTRAGENYX PHARM. DL-,001 |
| USA |
| Gesundheit |
| US90400D1081 / A1XCY0 |
| UP0 (Frankfurt) / RARE (NASDAQ) |
| FRA:UP0, ETR:UP0, UP0:GR, NASDAQ:RARE |
| - |
| https://www.ultragenyx.co.. |
|
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company that focuses on the development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases. The com..
>Volltext.. |
| 1936.13 Mio. EUR |
| 2307.31 Mio. EUR |
| 529.94 Mio. EUR |
| -427.5 Mio. EUR |
| -487.27 Mio. EUR |
| -4.99 EUR |
| 725.34 Mio. EUR |
| 178.44 Mio. EUR |
| -374.53 Mio. EUR |
| 1.28 |
| 14.46% |
| 1.58% |
| - |
| - |
| - |
| ULTRAGENYX |
| 13.02.26 |
|
||||
|